S&P 500
5.318,51 +15,24 (+0,29%) Nasdaq
16.795,58 +109,62 (+0,66%) NIKKEI 225
39.069,68 +282,30 (+0,73%) Dólar/Euro
1,0867 -0,0005 (-0,04%) Petróleo Brent
83,65 -0,33 (-0,39%) Bitcoin EUR
62.315,17 +847,30 (+1,38%)
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc.
3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, GA 30326
United States
844 722 6333
https://www.alzamend.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 4
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Stephan Jackman | CEO & Director | 434,24k | N/A | 1977 |
| Mr. David J. Katzoff | Chief Financial Officer | 116,67k | N/A | 1963 |
| Mr. Milton Charles Ault III | Founder & Vice Chairman | N/A | N/A | 1970 |
| Mr. Henry C. W. Nisser Esq. | Executive VP, General Counsel & Director | 50k | N/A | 1969 |
| Mr. Kenneth S. Cragun CPA | Senior Vice President of Finance | N/A | N/A | 1961 |
Descripción
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Gobierno corporativo
El ISS Governance QualityScore de Alzamend Neuro, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
